[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"remission\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:remission":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,81,140,167],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100650682","effectiveness-of-a-low-calorie-diet-combined-with-intensive-lifestyle-intervention-using-integrated-personalized-diabetes-management-for-achieving-diabetes-remission-in-patients-with-type-2-diabetes-mellitus-100650682",false,"NCT07748949","Effectiveness of a Low-Calorie Diet Combined With Intensive Lifestyle Intervention Using Integrated Personalized Diabetes Management for Achieving Diabetes Remission in Patients With Type 2 Diabetes Mellitus","Effectiveness of a Low-Calorie Diet Combined With Intensive Lifestyle Intervention Using Integrated Personalized Diabetes Management for Achieving Diabetes Remission in Patients With Type 2 Diabetes Mellitus: A Randomized Controlled Trial","REMIT-DM","Inclusion Criteria:\n\n* Diagnosed with type 2 diabetes mellitus with HbA1c level of 6.0 to 9.0%. Participants with HbA1c of 6.0 to 6.4% were required to be receiving oral glucose lowering medication.\n* Diagnosed with type 2 diabetes mellitus for less than 6 years.\n* Body mass index of 23 kg\u002Fm2 or greater.\n\nExclusion Criteria:\n\n* Receiving more than two oral glucose-lowering medications.\n* Receiving insulin therapy.\n* Use of a glucagon-like peptide-1 receptor agonist (GLP-1 RA) within 3 months before study enrollment.\n* Use of medications known to affect HbA1c within 3 months before study enrollment, including corticosteroids, vitamin C (excluding vitamin C obtained from natural dietary sources or fruits), vitamin E, trimethoprim-sulfamethoxazole, or hydroxyurea.\n* History of diabetic ketoacidosis or hyperglycemic hyperosmolar state within the previous 6 months.\n* Unstable psychiatric disorders within the previous 2 years, including major depressive disorder, bipolar disorder, or schizophrenia.\n* Pregnant or breastfeeding women, or women planning to become pregnant within 12 months.\n* Presence of any of the following medical conditions based on medical history and clinical records, including chronic kidney disease with an estimated glomerular filtration rate less than 45 mL\u002Fmin\u002F1.73 m2, liver cirrhosis or hepatitis with alanine aminotransferase or aspartate aminotransferase more than 3 times the upper limit of normal, chronic alcohol abuse, hypothyroidism with thyroid-stimulating hormone more than 10 uIU\u002FmL, HIV infection, anemia (hemoglobin less than 10 g\u002FdL), iron deficiency, vitamin B12 deficiency, folate deficiency, thalassemia, glucose-6-phosphate dehydrogenase deficiency, hemolytic anemia, or hemoglobin more than 16 g\u002FdL, heart failure or ischemic heart disease within the previous 6 months.\n* History of blood donation or blood transfusion within the previous 3 months.\n* Uncontrolled diabetic retinopathy or other uncontrolled retinal disease, including maculopathy, based on medical records.\n* Signs, symptoms, or a history of malignancy within 5 years before screening, except for basal cell carcinoma, squamous cell carcinoma of the skin, or other carcinoma in situ.\n* Major surgery within 90 days before enrollment or planned major surgery within 6 months after enrollment.\n* No access to a smartphone capable of supporting the study application and internet-based data transmission.\n* Unable to maintain communication with the study investigators according to the study protocol.","ALL","18 Years","70 Years",{"count":21,"type":22},54,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to determine whether a low-calorie diet combined with intensive lifestyle intervention using Integrated Personalized Diabetes Management (iPDM) is more effective than standard care in achieving diabetes remission in adults with overweight and type 2 diabetes mellitus. The study will also evaluate the effects of the intervention on metabolic and clinical outcomes associated with diabetes remission.\n\nThe main questions it aims to answer are:\n\n* Does a low-calorie diet combined with intensive lifestyle intervention using iPDM increase the proportion of participants who achieve diabetes remission compared with standard care?\n* Does the intervention improve metabolic and patient-centered outcomes, including glycemic control, body weight, body composition, Time in Range (TIR) measured by continuous glucose monitoring (CGM), quality of life, and cost-effectiveness?\n\nResearchers will compare participants receiving a low-calorie diet combined with intensive lifestyle intervention using iPDM with participants receiving standard diabetes care to determine whether the intervention is more effective in achieving diabetes remission and improving metabolic health.\n\nParticipants will:\n\n* Be randomly assigned to either the intervention group or the standard care group.\n* Attend study visits for assessments of diabetes-related clinical and metabolic outcomes throughout the 6-month study.\n* If assigned to the intervention group, consume two low-calorie meal replacements per day and follow an individualized meal plan providing no more than 1,200 kcal per day during the first 3 months (intensive phase), together with a personalized exercise program, continuous glucose monitoring (CGM), and lifestyle counseling delivered via telemedicine every 2 weeks. During the following 3 months (maintenance phase), continue lifestyle modification with reinforcement sessions delivered via telemedicine every 4 weeks while following a meal plan providing no more than 1,500 kcal per day.",[28,29,30,31],"Type 2 Diabetes","Obesity & Overweight","Remission","Lifestyle Intervention",[33,28,34,35],"Diabetes remission","Obesity","Lifestyle intervention","RECRUITING","2026-07-31",{"date":39,"type":40},"2026-08-06","ACTUAL",{"date":42,"type":40},"2026-06-17",{"date":44,"type":22},"2027-07-31",{"name":46,"class":47},"Chulalongkorn University","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},"100595302","association-between-exercise-patient-reported-outcomes-and-clinical-events-in-adult-cancer-survivors-100595302","NCT07030686","Association Between Exercise, Patient-Reported Outcomes, and Clinical Events in Adult Cancer Survivors","Inclusion Criteria:\n\nTarget trial (ideal RCT)\n\n* Adult (≥18 years of age) patients with history of primary invasive cancer under surveillance at Memorial Sloan Kettering Cancer Center (MSK).\n* Completion of an exercise survey (baseline) as part of MSK Cancer Survivorship Program and completion of a historical survey in the MSK Cancer Survivorship Program 9-15 months (time th) prior reporting non-exercising status \\[i.e., reporting \\\u003C10 metabolic equivalent-hours per week (MET-h\u002Fweek)\\]. Patients completing an additional exercise survey between th and baseline are excluded.\n* No evidence of recurrent or metastatic disease in the 15 months prior to the baseline exercise assessment\n* Completion of all definitive primary adjuvant therapy (e.g., chemotherapy, radiotherapy, targeted therapy) at least 3 months prior to completion of the historical exercise survey in a MSK Cancer Survivorship Program. Adjuvant hormonal therapy is permitted at any time.\n* Undergoing surveillance in the Cancer Survivorship Program at MSK\n\nEmulation using observational data\n\n* Adult (≥18 years of age) cancer survivors under surveillance at Memorial Sloan Kettering Cancer Center (MSK) between 2011 and 2023.\n* Assessment of self-reported exercise status via completion of an exercise survey as part of MSK Cancer Survivorship Program standard intake (baseline assessment).\n* Non-exercising (i.e., reporting \\\u003C5 MET-h\u002Fweek) via completion of an exercise survey as part of MSK Cancer Survivorship Program standard intake 9-15 months prior to the baseline exercise assessment (historical exercise survey).\n* Documented history of the following absolute contraindications to moderate-intensity exercise at any time prior to the baseline exercise assessment, assessed using the Elixhauser ICD codes: Congestive heart failure, valvular disease, chronic pulmonary disease, or renal failure.\n* No evidence of recurrent or metastatic disease via radiological or pathological in EMR in the 15 months prior to the baseline exercise assessment.\n* Completion of all definitive primary adjuvant therapy (e.g., chemotherapy, radiotherapy, targeted therapy) at least 3 months prior to completion of historical exercise survey (i.e., at least 3 months prior to t-1) as part of MSK Cancer Survivorship Program standard intake. Adjuvant endocrine therapy is permitted.",true,{"count":57,"type":22},1000,"OBSERVATIONAL","This protocol is a retrospective study using observational data to conduct a target trial emulation to examine the association of exercise on cancer specific endpoints and other clinical outcomes in cancer survivors.",[61,62,63,64,30],"Survivorship","Recurrent","Recurrence","Cancer",[61,66,67,68,69,70,71],"Exercise","cancer survivor","adult cancer survivor","no evidence of disease","20-101","Memorial Sloan Kettering Cancer Center","2026-04-27",{"date":74,"type":40},"2026-04-28",{"date":76,"type":40},"2020-03-19",{"date":78,"type":22},"2027-03-19",{"name":71,"class":47},4,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":91,"briefSummary":93,"conditions":94,"keywords":118,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":48},"100495785","phase-2-mt2021-08t-cell-receptor-alphabeta-depletion-pbsc-transplantation-for-heme-malignancies-100495785","NCT05735717","MT2021-08T Cell Receptor Alpha\u002FBeta Depletion PBSC Transplantation for Heme Malignancies","Phase II, Open-Label, Prospective Study of T Cell Receptor Alpha\u002FBeta Depletion (A\u002FB TCD) Peripheral Blood Stem Cell (PBSC) Transplantation for Children and Adults With Hematological Malignancies","Inclusion Criteria:\n\n* Histological confirmation of hematological malignancies\n* Acute leukemias\n* Acute Myeloid Leukemia (AML) and related precursor neoplasms\n* Favorable risk AML is defined as having one of the following:\n* Acute lymphoblastic leukemia (ALL)\u002Flymphoma\n* Myelodysplasia (MDS) IPSS INT-2 or High Risk (i.e. RAEB, RAEBt) or Refractory Anemia with severe pancytopenia, transfusion dependence, or high risk cytogenetics or molecular features.\n* Age 60 years of age or younger at the time of consent\n* Karnofsky performance status ≥ 70% or Lansky play score 50% for ≤16 years of age.\n* Adequate organ function\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding.\n* Active uncontrolled infection within 1 week of starting preparative therapy\n* Known seropositive for HIV or known active Hepatitis B or C infection with detectable viral load by PCR.\n* Any prior autologous or allogeneic transplant\n* CML blast crisis\n* Active central nervous system malignancy","60 Years",{"count":90,"type":22},70,[92],"PHASE2","This is a phase II, open-label, prospective study of T cell receptor alpha\u002Fbeta depletion (TCR α\u002Fβ TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies. This is a safety\u002Ffeasibility study of the investigational procedure\u002Fproduct.",[95,96,30,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117],"Hematologic Malignancy","Acute Leukemia","Acute Myeloid Leukemia","Acute Lymphoblastic Leukemia","AML","TP53","Intrachromosomal Amplification of Chromosome 21","Cytogenetic Abnormality","CNS Leukemia","Minimal Residual Disease","Myelodysplasia","Juvenile Myelomonocytic Leukemia","Somatic Mutation","PTPN11 Gene Mutation","N-RAS Gene Amplification","Neurofibromatosis 1","NF1 Mutation","CBL Gene Mutation","Monosomy 7","Chromosome Abnormality","Fetal Hemoglobin","Lymphoblastic Lymphoma","High Grade Non-Hodgkin's Lymphoma, Adult",[119,120,121,122,123,124,125,126,127,128,129,130],"Bu","Flu","G-CSF","GFSR","aGVHD","HCT","MAC","Mel","PBSCT","PTLD","RECIST","TCR","2026-03-31",{"date":133,"type":40},"2026-04-06",{"date":135,"type":40},"2023-05-11",{"date":137,"type":22},"2030-11-30",{"name":139,"class":47},"Masonic Cancer Center, University of Minnesota",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":147,"minAge":18,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":23,"phases":150,"briefSummary":151,"conditions":152,"keywords":154,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":166},"100558629","impact-of-a-multidisciplinary-assessment-in-day-hospitalization-versus-standard-care-on-the-deployment-of-supportive-oncology-care-recommended-by-the-personalized-post-cancer-plan-in-patients-at-the-end-of-initial-treatment-for-gynecological-ovarian-and-endometrial-cancer-endometrial-cancer-100558629","NCT06553612","Impact of a Multidisciplinary Assessment in Day Hospitalization Versus Standard Care on the Deployment of Supportive Oncology Care Recommended by the Personalized Post-cancer Plan in Patients at the End of Initial Treatment for Gynecological Ovarian and Endometrial Cancer Endometrial Cancer","AFTERGYN2","Inclusion Criteria:\n\n* Patient \\> 18 years\n* Patients in remission from first-line treatment of endometrial or ovarian\u002Ftumor\u002Fperitoneal cancer.\n* Patient who has completed her initial treatment; patients on maintenance therapy are eligible.\n* Fluency in French\n* Patient with access to a telephone line\n* Patient affiliated to a social security scheme\n* Signature of informed consent prior to any specific study procedure\n\nExclusion Criteria:\n\n* Any associated medical or psychiatric condition that could compromise the patient's ability to participate in the study\n* Patient with locoregional or metastatic recurrence\n* Patient deprived of liberty, under guardianship or curatorship\n* Simultaneous participation in a therapeutic clinical trial","FEMALE",{"count":149,"type":22},268,[25],"This project proposes a structuring of supportive oncology care for the recovery phase after gynecological cancer (ovarian\u002Ftrope\u002Fperitoneum or endometrium). Patients will be divided into three groups based on the identification of oncological support care needs. Patients with supportive oncology care needs will be randomized into two groups: the experimental group, receiving a personalized post-cancer plan with a multidisciplinary assessment of supportive oncology care needs in a day hospital and coordinated follow-up by the referring study nurse, and the control group, receiving a personalized post-cancer plan without a day hospital. Randomization will be stratified according to tumor location (ovary vs. endometrium), use of supportive oncology care during treatment, and treatment center. Patients with no need for supportive oncology care will be followed in an observational cohort. The main objective is to identify and manage the supportive oncology care needs of patients in remission from endometrial or ovarian cancer to improve their quality of life and post-treatment follow-up. A medico-economic analysis will be performed.",[153,30],"Gynecologic Cancer",[155,156],"supportive oncology care","personalized post-cancer plan","2026-01-07",{"date":159,"type":40},"2026-01-08",{"date":161,"type":40},"2024-06-07",{"date":163,"type":22},"2028-06-07",{"name":165,"class":47},"Centre Francois Baclesse",13,{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":174,"enrollmentInfo":175,"targetDuration":4,"studyType":23,"phases":177,"briefSummary":178,"conditions":179,"keywords":181,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":48},"100550819","changing-trunk-muscle-activation-in-patients-with-recurrent-low-back-pain-in-remission-100550819","NCT06452030","Changing Trunk Muscle Activation in Patients With Recurrent Low Back Pain in Remission","MAS","Inclusion Criteria:\n\n1. People between 18-65 years old\n2. Having recurrent non-specific low back pain (LBP) in remission at enrolment:\n\n   * At least 2 episodes of LBP\u002Fyear, with an 'episode' implying pain lasting a minimum of 24 hours which is preceded and followed by at least 1 month without LBP\n   * Minimum LBP intensity during episodes should be ≥2\u002F10 on a numeric rating scale (NRS) from 0 to 10\n   * During remission the NRS intensity for LBP should be 0-1\u002F10.\n3. Having a dominant flexion movement pattern\u002F neutral movement pattern\n\nExclusion Criteria:\n\n1. People \\\u003C18 years old or \\>65 years old\n2. Having any other type of non-specific LBP (acute, subacute, chronic).\n3. Having an active extension movement pattern\n4. Having any type of blood clotting disorder\n5. People with upper-limb complaints that prevent them from exerting (maximum) force with their arms or hands.\n6. People that received specific sensorimotor control training or fascia-training in the previous year\n7. People with serious underlying conditions (e.g., multiple sclerosis) or severe scoliosis\n8. People with a history of spine surgery\n9. Pregnant women and women who have given birth in the year before enrolment","65 Years",{"count":176,"type":22},55,[25],"The first aim of the study is to investigate the effects of a single therapy session on trunk muscle activation and lumbopelvic sensorimotor control in persons with recurrent low back pain in remission.\n\nThe second aim of the study is to examine the convergent validity of (in)voluntary multifidus activation by means of inspection and palpation during two clinically assessed lumbopelvic sensorimotor control tests in persons with recurrent low back pain in remission. The convergent validity will be examined by calculating the relationship between (1) the clinical score of (in)voluntary multifidus activation, (2) back muscle activation during the same tests measured simultaneously with electromyography and (3) trunk muscle activation during other functional movements measured with electromyography.\n\nThe third aim of the study is to investigate the convergent validity of a left-right discrimination test by calculating the relationship between (1) the left-right discrimination test, (2) position-reposition test, (3) the Fremantle Back Awareness Questionnaire and (4) the Photograph Series of Daily Activities Scale.",[180,30],"Recurrent Low Back Pain",[182,183,66,184],"Low back pain","Motor control","Randomised Controlled Trial","2024-06-10",{"date":187,"type":40},"2024-06-11",{"date":189,"type":40},"2024-03-29",{"date":191,"type":22},"2025-10-01",{"name":193,"class":47},"University Ghent"]